Facts of Ibrance™ (palbociclib) Capsules 125mg ?
- Medicine Name: Ibrance™
- Generic Name: Palbociclib
- Approval Date: Feb 3, 2015
- Company Name: Pfizer Labs
- Available as (Form & Strength): Capsules: 125 mg, 100 mg, and 75 mg
What are the indications and usage?
IBRANCE ® is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.